Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Hypertension. 2018 May 18;72(1):44–55. doi: 10.1161/HYPERTENSIONAHA.118.10893

Table 1.

Published human studies of novel mechanisms for hypertension in HIV-infected adults

Year First Author Journal Study Design Country Sample Size % of HIV-infected on ART
HIV-infected HIV-uninfected
2005 Thiebaut Antivir Ther Prospective Cohort 21 countries (Europe, US and Australia) 17,179 0 84%
2006 Crane AIDS Prospective Cohort U.S.A. 444 0 100%
2006 Palacios HIV Med Prospective Cohort Spain 95 0 100%
2008 Baekken Nephrol Dial Cross-sectional Norway 495 2091 72%
2008 Baekken J Hypertens Prospective Cohort Norway 542 24,968 71%
2009 Crane HIV Med Cross-Sectional U.S.A. 347 0 69%
2012 Freitas J Clin Hypertens Cross-Sectional Portugal 368 0 100%
2013 Glyn J Hum Hypertens Cross-Sectional South Africa 53 129 0%
2013 Hadigan Am J Nephrol Prospective Cohort U.S.A. 182 0 100%
2013 Manner HIV Med Prospective Cohort Norway 42 0 0%
2013 Manner J Clin Hypertens Prospective Cohort Norway 434 0 57%
2014 Morimoto Nutrition Cross-Sectional Brazil 285 0 79%
2014 Peck BMC Medicine Cross-Sectional Tanzania 301 153 50%
2014 Tenorio J Infect Dis Case-Control U.S.A. 458 0 100%
2015 Rokx AIDS Res Hum Clinical Trial Netherlands 50 0 100%
2015 Wensink PLoS One Cross-Sectional South Africa 903 0 87%
2016 Castley PLoS One Cross-Sectional Australia 475 0 77%
2016 Maffongelli AIDS Prospective Cohort Italy 116 0 100%
2016 Nduka Int J Cardiol Cross-sectional Nigeria 406 0 75%
2016 Pirro Sci Rep Cross-Sectional Italy 170 0 100%
2016 van Zoest Clin Infect Dis Prospective Cohort Netherlands 527 517 95%
2017 Ascher Hypertension Prospective Cohort U.S.A. 823 267 59%
2017 Ding AIDS Res Hum Cross-Sectional China 345 345 87%
2017 Rodriguez-Arboli PLoS One Prospective Cohort Tanzania 834 0 76%